UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM SD

Specialized Disclosure Report

 

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2013.

 

 

---

 

 

 

 

Section 1.Conflict minerals disclsosure

 

Item 1.01 Conflict Minerals Disclosure and Report, Exhibit

Pacific Biosciences of California, Inc. evaluated its current product lines and determined that certain products it manufactures or contracts to manufacture contain tin, tungsten, tantalum and/or gold. The survey of its suppliers determined that its supply chain is “DRC conflict undeterminable” and, as a result, it is filing a Conflict Minerals Report. A copy of Pacific Biosciences of California, Inc.’s Conflict Minerals Report is filed as Exhibit 1.02 hereto.  A copy of this Form SD and the Conflicts Minerals Report are publicly available at www.pacb.com.

 

Item 1.02  Exhibit

See Item 2.01

 

Section 2.Exhibits

 

Item 2.01 Exhibits

The following exhibit is filed as part of this report:

Exhibit 1.02 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

---

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 30, 2014

---

Exhibit 1.02

 

Conflict Minerals Report of Pacific Biosciences of California, Inc.

in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934

This is the Conflict Minerals Report (“CMR”) of Pacific Biosciences of California, Inc. (“PACB”) for calendar year 2013 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 34-67716 for definitions to the terms used in this Report, unless otherwise defined herein.

I. Company Overview

 

PACB develops, manufactures and markets an integrated platform for high resolution genetic analysis. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, PACB created a technology platform called single molecule, real-time, or SMRT, technology. PACB’s initial focus is to offer SMRT technology to the DNA sequencing market where PACB has developed a third generation sequencing platform, the PacBio RS and PacBio RS II sequencing systems. The PacBio RS and PacBio RS II are instruments that use PACB’s proprietary consumables, including PACB’s SMRT Cells and reagent kits that are used to prepare and sequence DNA samples.

 

PACB conducted an analysis of its products and found that the SEC defined “conflict minerals,” namely tin, tantalum, tungsten, and gold (“3TG”), can be found in its PacBio RS and PacBio RS II instruments. Therefore, the products that PACB manufactures are subject to the reporting obligations of Rule 13p-1. PACB’s remaining products, including SMRT Cells and reagent kits, do not contain 3TG.

II. Due Diligence

In accordance with the rules, PACB undertook due diligence to determine the conflict minerals status of the necessary conflict minerals used in its products. In conducting its due diligence, PACB implemented the  Organization for Economic Co-operation and Development (OECD) Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas (OECD 2011) (“OECD Framework”), an internationally recognized due diligence framework.  For the purpose of the required Reasonable Country of Origin Inquiry (“RCOI”), PACB continued to receive supply chain responses through April 30, 2014.

PACB’s due diligence measures were based on the conflict-free sourcing initiative (“CFSI”) of the Electronic Industry Citizenship Coalition (“EICC”) and Global e-Sustainability Initiative (“GeSI”). As a company in the DNA sequencing market, PACB is several levels removed from the actual mining of 3TG. PACB does not make purchases of raw ore or unrefined 3TG and makes no purchases of 3TG directly from the Democratic Republic of the Congo or an adjoining country (together, the “Covered Countries”).

PACB performed the following due diligence measures:

 

 

---

 

III. Conclusion

 

Despite having conducted a good faith reasonable country of origin inquiry, PACB has concluded that its supply chain remains “DRC conflict undeterminable.” PACB reached this conclusion because it has been unable to determine the origin of all 3TG used in certain integrated circuits and other components used in the manufacturing of its instruments.  The report presented herein is not audited as Rule 13p-1 provides that if a registrant’s products are “DRC conflict undeterminable” in 2013 or 2014, the CMR is not subject to an independent private sector audit.

IV. Future Due Diligence Measures

In the next compliance period, PACB intends to implement steps to improve the information gathered from its due diligence. The steps include:

 

 

 

 

 

 

 

---